Investment Rating - The report maintains a "Hold" rating for the company [8][15]. Core Insights - The company achieved a revenue of 1.176 billion yuan in 2023, representing a year-on-year growth of 20.63%. The net profit attributable to shareholders was 170 million yuan, up 36.3% year-on-year [1]. - The smart manufacturing segment saw a revenue of 850 million yuan, growing by 20.92%, while the rehabilitation medical segment generated 325 million yuan, with a growth of 19.89% [1]. - The company is focusing on the application of brain-computer interfaces in rehabilitation, aiming to shift from passive to active recovery [1]. - R&D expenses increased to 73.5 million yuan, a growth of 15.46%, with a R&D expense ratio of 6.25% [1]. - The company’s management expense ratio decreased to 7.31%, and the sales expense ratio fell to 9.5%, indicating improved profitability [1]. Summary by Sections Performance Overview - In 2023, the company reported total revenue of 1.176 billion yuan, a 20.63% increase year-on-year. The net profit attributable to shareholders was 170 million yuan, reflecting a 36.3% increase [1]. - For Q4 2023, revenue was 247 million yuan, down 11.56% year-on-year, and net profit was 42 million yuan, down 14.39% [1]. Smart Manufacturing - The smart manufacturing segment generated 850 million yuan in revenue, a 20.92% increase, with a net profit of 85 million yuan, up 42.92% [1]. - The company is expanding its capabilities in synthetic biology and green manufacturing, contributing to growth in non-pharmaceutical sectors [1]. Rehabilitation Medical - The rehabilitation medical segment achieved 325 million yuan in revenue, a 19.89% increase, with a net profit of 85 million yuan, up 30.30% [1]. - The company collaborates with multiple educational institutions to explore brain-computer interface applications in rehabilitation [1]. R&D Investment - R&D expenses reached 73.5 million yuan, a 15.46% increase, with a R&D expense ratio of 6.25% [1]. - The company has obtained 10 new medical device registrations in 2023, bringing the total to 94 [1]. Cost and Profitability - The management expense ratio decreased to 7.31%, and the sales expense ratio fell to 9.5% [1]. - The gross profit margin improved to 42.93%, and the net profit margin increased to 14.27% [1].

Investment Rating - The report maintains a "Buy" rating for the company [10] Core Views - The company's performance in 2023 was under pressure due to a sluggish global macroeconomic environment and a slow recovery in the downstream 3C sector. However, with government policies encouraging the replacement of aging industrial machinery and a recovery driven by new technologies in the 3C market, along with an enhanced market position in the new energy sector, the company is expected to experience new growth [9][13] - The report adjusts the profit expectations for 2024-2025 and introduces a profit forecast for 2026, estimating revenues of 39.46 billion, 43.58 billion, and 48.23 billion yuan for 2024, 2025, and 2026 respectively, with corresponding net profits of 4.06 billion, 4.99 billion, and 6.17 billion yuan [9][13] Financial Summary - In 2023, the company achieved operating revenue of 35.29 billion yuan, a year-on-year decrease of 22.04%, and a net profit attributable to the parent company of 1.94 billion yuan, down 41.95% year-on-year. The fourth quarter saw a revenue of 7.43 billion yuan, a year-on-year increase of 15.07% [9][12] - The company’s overseas revenue grew significantly, reaching 1.45 billion yuan in 2023, up 74.84% year-on-year, while domestic revenue was 33.84 billion yuan, down 23.85% [9][12] - The main business of CNC machine tools generated revenue of 34.27 billion yuan, accounting for 97.10% of total revenue, with a year-on-year decrease of 22.51% [9][12] - The report highlights a weak demand in the machine tool market, with a decline in orders due to low global manufacturing PMI and insufficient recovery in domestic market demand [9][12] - The company is expected to benefit from national policies supporting the replacement of machines over ten years old, which will release demand for CNC machine upgrades and replacements [9][12] Future Outlook - The 3C business shows significant recovery momentum, with a notable increase in shipments of the company's flagship drilling and tapping machines, which saw over 120% year-on-year growth in the fourth quarter [9][12] - The company is expanding into new energy applications, focusing on lightweight and electric vehicle developments, and has launched a new lightweight gantry machining center as a high-end supporting product for integrated die-casting [9][12]

Investment Rating - The report upgrades the investment rating to "Buy" with a target price of 29.58 CNY, reflecting the company's growth potential and market positioning [15][19]. Core Insights - The company, Micro Electrical Physiology (688351), is a leading domestic player in the cardiac electrophysiology market, having established a comprehensive product lineup that includes both radiofrequency and cryoablation technologies. It is one of the few global manufacturers to offer a complete solution for three-dimensional cardiac electrophysiology equipment and consumables [11][20]. - The company has demonstrated robust revenue growth, with a CAGR of 31.41% from 2015 to 2023, achieving a revenue of 329 million CNY in 2023, a year-on-year increase of 26.46% [11][69]. - The report highlights the significant market potential for electrophysiology, with over 30 million patients suffering from arrhythmias in China. The demand for catheter ablation procedures is expected to grow rapidly, driven by advancements in technology and increasing clinical adoption [11][20]. Summary by Sections Company Overview - Micro Electrical Physiology was established in 2010 and focuses on innovative medical devices for electrophysiology intervention and ablation treatment. The company has made significant technological advancements, breaking the long-standing foreign monopoly in this field [61][62]. - The company has a diverse shareholder structure with no controlling shareholder, ensuring a balanced governance model [64]. Financial Overview - The company has maintained steady revenue growth, with a notable recovery post-pandemic. The revenue for 2023 was impacted by centralized procurement policies, but future growth is expected as these pressures ease [69]. - The net profit for 2023 reached 5.47 million CNY, marking an 84.06% increase from the previous year, indicating improving profitability as the company navigates the procurement landscape [69]. Market Potential - The report emphasizes the vast unmet demand in the electrophysiology market, with a projected increase in catheter ablation procedures. The market for atrial fibrillation ablation is expected to grow significantly, with the number of procedures projected to reach 252,000 by 2024 [10][11]. - The company is well-positioned to capitalize on this growth, with a strong pipeline of innovative products and a focus on expanding its market share domestically and internationally [11][20]. Product Development - Recent product approvals, including the TrueForce® pressure catheter and the Columbus® three-dimensional electrophysiology mapping system, enhance the company's competitive edge and market presence [11][62]. - The company is actively developing new technologies, including pulse field ablation and renal denervation, which are expected to open new growth avenues in the future [11][20].

] y r t s u d n I _ e l b a T [ [ 阳Ta 光bl 电e_ 源T （itl 3e 0] 0 274）财报点评 公 司 业绩保持高增，光储需求旺盛 研 挖掘价值 投资成长 究 / [Table_Rank] 增持 电 （维持） 气 设 2024 年 04 月 24 日 备 / 证 [东Ta方bl财e_富Au证th券or研] 究所 券 [【Ta投bl资e_要Su点mm】ar y] 证券分析师：周旭辉 研 究 证书编号：S1160521050001 报 证券分析师：朱晋潇 告  公司发布2023年度报告和2024年一季报，业绩继续保持高增。2023 证书编号：S1160522070001 年公司营业收入722亿元，同比增长79%，归母利润94.4亿，同比增 电话：021-23586740 长 163%。公司毛利率从 2022 年的 24.5%提升到 30.4%，净利润率从 [相T对ab指le数_P表ic现Qu ote] 9.2%提升到13.3%，净资产收益率从2022年的21%提升到41%。2024 年一季度，公司收入同比略增，利润保持增长，归母净利 21 亿元， 19.01% 同比 ...

] y r t s u d n I _ e l b a T [ [ 中Ta 际bl 旭e_ 创T （itl 3e 0] 0 308）2024年一季报点评 公 司 行业高景气，高端光模块持续迭代 研 挖掘价值 投资成长 究 / [Table_Rank] 增持 信 （首次） 息 技 2024 年 04 月 24 日 术 / 证 [东Ta方bl财e_富Au证th券or研] 究所 券 [【Ta投bl资e_要Su点mm】ar y] 证券分析师：邹杰 研 究 证书编号：S1160523010001 报 联系人：刘琦 告  公司发布 2024 年一季报：公司 1Q24 年实现营收 48.42 亿元（同比 +163.59%），归母净利润10.09亿元（同比+303.84%）。公司一季度收 电话：021-23586475 入、毛利率、净利率、归母净利润均同比向好。通常公司每年一季度 [相T对ab指le数_P表ic现Qu ote] 联 系 方 式 ： 会执行新的价格年降，产品结构上，400G在Q1上量比800G相对快一 021-23586305 111.11% 些，毛利较 800G 低一些，两者对综合毛利率会有一些影响。202 ...

] y r t s u d n I _ e l b a T [ [ 芒Ta 果bl 超e_ 媒T （itl 3e 0] 0 413）2023年报&一季报点评 公 司 会员规模再创新高，“四平台”多元发 研 究 展 挖掘价值 投资成长 / [Table_Rank] 传 增持 （维持） 媒 互 2024 年 04 月 24 日 联 网 / [东Ta方bl财e_富Au证th券or研] 究所 证 券 [【Ta投bl资e_要Su点mm】ar y] 证券分析师：高博文 研 证书编号：S1160521080001 究 报  公司发布2023年报和2024年一季报。 证券分析师：陈子怡 告 证书编号：S1160522070002 2023 年，公司实现营业收入 146.28 亿元，同比增长 4.66%；实现归 证券分析师：潘琪 母净利润35.56亿元，同比增长90.73%；实现扣非归母净利润16.95 证书编号：S1160524040001 亿元，同比增长5.70%。 联系人：陈子怡 电话：021-23586305 2024年一季度，公司实现营业收入33.24亿元，同比增长7.21%；实 [相T对ab指le数_P表ic现Q ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [20]. Core Views - In the short term, the domestic substitution of high-end CNC machine tools combined with increased overseas export demand is expected to lead to a return to positive growth in 2024. In the medium to long term, the company is actively laying out in high-end machine tools, new energy vehicles, and humanoid robot industry chains, which is expected to expand its growth space [11][24]. - The company's revenue for 2024-2026 is projected to be 46.33 billion, 56.23 billion, and 67.09 billion yuan, with corresponding net profits of 1.90 billion, 2.70 billion, and 3.69 billion yuan, leading to EPS of 0.19, 0.27, and 0.37 yuan, and PE ratios of 45, 32, and 23 times respectively [11][12]. Financial Performance Summary - In 2023, the company achieved a revenue of 37.61 billion yuan, a year-on-year decrease of 8.29%, and a net profit attributable to shareholders of 52.26 million yuan, down 81.00% year-on-year. The fourth quarter of 2023 saw a revenue of 9.32 billion yuan, with a year-on-year decrease of 7.23% [23]. - The gross profit margin for 2023 was 17.7%, a decrease of 1.12 percentage points year-on-year, with the machine tool segment's gross margin at 16.72% [18]. - The company plans to raise no more than 1.23 billion yuan for projects including the innovation base for high-end industrial mother machines and the R&D of rolling functional components in the new energy vehicle sector [19].

[Table_Title] 鼎通科技（688668）2024年一季报点评 2024 年 04 月 24 日 公司发布 2024 年一季报：公司 1Q24 年实现营收 1.94 亿元（同比 +19.73%），归母净利润 0.18 亿元（同比-45.11%）。公司一季度收入、 毛利率、净利率、归母净利润均环比向好，呈现复苏态势。 公司同时发布 2023 年年报：2023 公司营业收入同比下降 18.65%，归 母净利润同比下降 60.48%，主要是受全球宏观经济低迷及通信市场疲 软的影响，需求疲软和消耗往期库存的双重影响下，壳体类产品的需 求出现明显下滑，导致通讯营业收入较大下降；汽车连接器产品虽需 求良好，但竞价激烈；因此由于需求产能的不饱和以及成本的压力， 公司整体的毛利率有所下滑，利润下降。2023 公司前五名合并集团客 户合计销售额占当期营业收入的比例为 83.96%，主要客户为莫仕、安 费诺、中航光电、泰科电子、比亚迪等连接器行业内知名企业。 通讯业务方面：2023 年上半年，公司通讯连接器业务面临前所未有的 挑战，终端客户的需求低于预期，但自 2023 年三季度末开始，市场 形势逐渐好转，通讯连接器产 ...

] y r t s u d n I _ e l b a T [ [ 德Ta 赛bl 西e_ 威T （itl 0e 0] 2 920）2023年报&一季报点评 公 24Q1业绩增长继续兑现，海外开拓新项 司 研 目订单充足 挖掘价值 投资成长 究 / [Table_Rank] 增持 交 （首次） 运 设 2024 年 04 月 23 日 备 / 证 [东Ta方bl财e_富Au证th券or研] 究所 券 [【Ta投bl资e_要Su点mm】ar y] 证券分析师：邹杰 研 究 证书编号：S1160523010001 报 联系人：袁泽生 告  2024年3月28日，德赛西威公告2023年年报，并在4月22日披露 一季度业绩预告。2023年公司实现营业收入 219.08 亿元，同比增长 电话：021-23586475 46.71%；实现归母净利润15.47亿元，同比增长30.65%。单四季度来 [相T对ab指le数_P表ic现Qu ote] 看，公司实现营收74.38亿元，同比增长54.24%，环比增长29.44%； 64.51% 实现归母净利润5.86亿元，同比增长19.29%，环比增长66.00%。公 46.97 ...

| --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | 发布。 | | | ...